TSO3 Inc. J Received its Third Buy in a Row

By Ryan Adsit

TSO3 Inc. J (TSX: TOS), has been popular among analysts lately as after Scotiabank and GMP FirstEnergy rated the stock a Buy this past month, there is another positive note, this time from Canaccord Genuity. Yesterday, analyst Neil Maruoka gave a Buy rating to TOS and set a C$5.25 price target.

According to TipRanks.com, Maruoka is a 1-star analyst with an average return of -0.9% and a 37.1% success rate. Maruoka covers the Healthcare sector, focusing on stocks such as Merus Labs International, Cardiome Pharma Corp, and Concordia Healthcare.

Currently, the analyst consensus on TSO3 Inc. J is Strong Buy and the average price target is C$4.50, representing a 43.8% upside.

In a report issued on July 27, RBC Capital also reiterated a Buy rating on the stock with a C$4.25 price target.

TSO3 Inc. J’s market cap is currently C$288.1M and has a P/E ratio of 0.

TSO3, Inc. engages in the business of medical devices. Its activities include manufacturing, sale; research and development, licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices.

The company’s shares closed on Friday at C$3.13.